Company: RGNT
Filing Date: 2025-12-05
Form Type: 6-K
Source: 0001213900-25-118725
Chunk: 0

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-12-05
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private
Issuer

Pursuant to Rule 13a-16
or 15d-16

under the Securities Exchange Act of 1934

For the month of December 2025

Commission file number: 001-42834

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐

CONTENTS</div>

On December 5, 2025, Regentis Biomaterials Ltd. (the “Company”)
closed its initial public offering (the “IPO”) of 1,250,000 ordinary shares, no par value per share (the “Ordinary
Shares”), pursuant to the terms of the underwriting agreement (the “Underwriting Agreement”) dated as of December 3,
2025, between the Company and ThinkEquity LLC, as representative of the several underwriters, which was registered
under the Securities Act of 1933, as amended (the “Securities Act”) by the Company’s
registration statement on Form F-1 (File No. 333-285692), originally filed with the Securities and Exchange Commission (the
“SEC”) on March 11, 2025, which, as subsequently amended, became effective automatically pursuant to Section 8(a) of the Securities
Act, on November 12, 2025. The Ordinary Shares were sold at an initial public offering price of $8.00 per Ordinary Share.

In connection with the IPO, the Company received
aggregate gross proceeds of approximately $10 million, before deducting underwriting discounts, commissions and before offering expenses.
ThinkEquity LLC served as sole book-running manager for the IPO. The Ordinary Shares were approved for listing on the NYSE American and
commenced trading under the symbol “RGNT” on December 4, 2025.

A copy of the Underwriting Agreement related to the IPO
is furnished herewith as Exhibit 1.1 and incorporated herein by reference.

The Company issued a press